Optimization of biologics to reduce treatment failure in inflammatory bowel diseases - Archive ouverte HAL Access content directly
Journal Articles Current Opinion in Pharmacology Year : 2020

Optimization of biologics to reduce treatment failure in inflammatory bowel diseases

(1) , (2) , (1) , (3) , (3, 1)
1
2
3

Abstract

Moderate to severe inflammatory bowel disease patients can fail to respond to conventional therapy and/or to biologic treatment. In the era of TNFα antagonists and other non-anti-TNF biologic drugs, it is important to review the literature on biologic treatment failure, which could be defined as primary non-response, secondary loss of response and intolerance. Therapeutic drug monitoring (TDM), that is, drug trough level and antidrug antibodies, should enable to determine the mechanisms of treatment failure and to optimize drug efficacy. There is a consensus on reactive TDM at the time of loss of response. Proactive TDM could be of interest during induction and/or maintenance, but randomized controlled trials are required.
Fichier principal
Vignette du fichier
S1471489220300503.pdf (374.97 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-02983219 , version 1 (21-09-2022)

Licence

Attribution - NonCommercial - CC BY 4.0

Identifiers

Cite

Aurélie Bourchany, Cyrielle Gilletta de Saint-Joseph, Anne Breton, Frédérick Barreau, Emmanuel Mas. Optimization of biologics to reduce treatment failure in inflammatory bowel diseases. Current Opinion in Pharmacology, 2020, 54, pp.51-58. ⟨10.1016/j.coph.2020.07.012⟩. ⟨hal-02983219⟩
20 View
3 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More